

# Dr. Ross A. Dunne

## Curriculum Vitae (short version)

February 13, 2026

brainHealth Manchester  
70 Daisybank Road  
Manchester M14 5QN  
✉ ross.dunne@gmmh.nhs.uk  
📞 0000-0003-2046-6193  
🌐 sadneurons  
in ross-dunne-gmdrc  
GMC: 7250794  
Specialist Register: 19/8/15



### Summary

Consultant in Old Age Psychiatry and Clinical Director of Greater Manchester Dementia Research Centre. Established UK's first psychiatrist-led CSF biomarker service (2022), scaled into Manchester Brain Health Centre with £35M industry investment. PI/Co-I on 30+ Phase I-III trials; research portfolio exceeding £15M. Focus: platform trials for disease-modifying therapies, molecular diagnostics, vascular cognitive impairment.

### Education & Qualifications

- 2010 **PgDipStat**, Trinity College Dublin
- 2010 **MRCPsych**, Royal College of Psychiatrists
- 2005 **MB BCH BAO**, Trinity College Dublin

### Current Appointments

- 2024– **NIHR-RDN NW England Dementia Clinical Lead**
- 2021– **Board Member/Dementia Theme Co-Lead**, Geoffrey Jefferson BRC
- 2020– **Theme Lead for Dementia**, Health Innovation Manchester
- 2019– **Clinical Director**, Greater Manchester Dementia Research Centre
- 2015– **Consultant in Old Age Psychiatry**, GMMH Foundation Trust

### Selected Leadership Roles

- 2019– **Clinical Director**, Greater Manchester Dementia Research Centre  
Leading NW's largest dementia research centre (7 staff, 9 ongoing studies). Managing commercial/grant portfolio across Phase I-III trials. Member of national Dementia Trials Network.
- 2022– **Founder/Clinical Lead**, Manchester Brain Health Centre  
Established UK's first psychiatrist-led CSF biomarker clinic. Scaled into comprehensive Brain Health Centre with molecular diagnostics, cardiovascular profiling, and risk reduction interventions. £35M industry investment.

### Recent Grants (Recent; £14M+ total)

- 2026–31 **Treating auditory impairment in MCI**, NIHR PGfAR, £3.4M, Co-App
- 2025–30 **AD-SMART Platform Trial**, MRC/DRI/ARUK, £7.5M, Co-I
- 2025–27 **Manchester Brain Health Centre**, AlzSoc, £1.5M, Clinical Director
- 2024–29 **READ-OUT Real world outcomes**, ARUK/AlzSoc/NIHR, £4.5M, Site PI
- 2023–28 **ANTLER75+ Depression withdrawal**, NIHR HTA, £1.95M, Site PI
- 2023–26 **All-in-One MCI imaging**, Alzheimer's Society, £384K, PI

### Awards & Honors

- 2025 **HSJ Award**, Best NHS Collaboration & Best Pharmaceutical Partnership
- 2024 **ACCIA National Clinical Impact Award Level N1**
- 2023 **HSJ Award**, Modernising Diagnostics (brainHealth Manchester)

### Clinical Trials Experience

- Overview PI/Co-I on 30+ trials across AD monoclonal antibodies (Aducanumab, Gantenerumab, AL002), AD therapeutics (semaglutide, tau ASO), neuropsychiatric symptoms, and biomarker/platform studies (AD-SMART, READOUT, AllinOne). Extensive Phase I-III experience.
- Current Gabriella (Roche), CELIA (Biogen), AD-SMART (MRC), ANTILER75+ (NIHR), CICERO (NIHR), AllinOne (Alz-Soc), READOUT (ARUK/NIHR), ABHAD (BRC)

### Innovation & Service Development

Brain Health	Established UK's first psychiatrist-led CSF biomarker clinic (2022). Personally developed lab protocols, scaled into Manchester Brain Health Centre with comprehensive molecular diagnostics, cardiovascular profiling, and risk reduction using Motivational Interviewing. Advised 10+ UK/international sites on replication.
Regional MDT	Convened regional MDT (2024) with neurology, neuroradiology, nuclear medicine for safe implementation of monoclonal antibody therapies in AD.

## Selected Publications (h-index: 20+)

- [1] Dunne, R. Coulthard, E. "Tipping the scales towards routine APOE genotyping". In: *Journal of Neurology, Neurosurgery & Psychiatry* 94.9 (2023). Editorial, pp. 669–669. DOI: [10.1136/jnnp-2023-332045](https://doi.org/10.1136/jnnp-2023-332045).
- [2] Taylor, J. L. "Uncoupling of Ca<sup>2+</sup> sparks from BK channels in cerebral arteries underlies hypoperfusion in hypertension-induced vascular dementia". In: *Proceedings of the National Academy of Sciences* 120.33 (2023), e2307513120. DOI: [10.1073/pnas.2307513120](https://doi.org/10.1073/pnas.2307513120).
- [3] Dunne, R. A. "Mild cognitive impairment: the Manchester consensus". In: *Age and ageing* 50.1 (2021), pp. 72–80. DOI: [10.1093/ageing/afaa228](https://doi.org/10.1093/ageing/afaa228).
- [4] Semkovska, M. "Bitemporal versus high-dose unilateral twice-weekly electroconvulsive therapy for depression (EFFECT-Dep): a pragmatic, randomized, non-inferiority trial". In: *American Journal of Psychiatry* 173.4 (2016), pp. 408–417. DOI: [10.1176/appi.ajp.2015.15030372](https://doi.org/10.1176/appi.ajp.2015.15030372).
- [5] Dunne, R. A. McLoughlin, D. M. "Systematic review and meta-analysis of bifrontal electroconvulsive therapy versus bilateral and unilateral electroconvulsive therapy in depression". In: *The World Journal of Biological Psychiatry* 13.4 (2012), pp. 248–258. DOI: [10.3109/15622975.2011.608473](https://doi.org/10.3109/15622975.2011.608473).

Full publication list (30+ peer-reviewed articles): available on request or ORCID 0000-0003-2046-6193

## Research Skills

Clinical	Trial design/coordination, GCP, ethics, lumbar puncture, CSF biomarker processing. Rating scales: RBANS, CDR, ADAS-Cog, MADRS, MMSE, MoCA, PWV, audiometry.
Technical	R, Python, C++, mixed-effects modelling (lmer), TensorFlow/PyTorch, LaTeX, Linux/BASH, web development (Django, JavaScript). PgDipStat (TCD), ONS Safe Researcher, Google Python certification.
Current Study	BSc Mathematics (Open University, in progress)

## Teaching & Training

Undergraduate tutor (TCD, Cambridge, Manchester). Faculty member, Neurology Academy Sheffield. Registered trainer/educational supervisor for higher trainees in old age psychiatry.

## Service & Leadership

UK Brain Health Coalition	Founder member and Co-Chair (ARUK/AlzSoc). Lead national dissemination of early diagnosis approaches.
Grant Review	Co-chair, Alzheimer's Society UK (2022–25); Board member ARUK (2023–25), Alzheimer Society Ireland (2023)
Trial Oversight	TSC member and chair COBALT (NIHR EME). Peer reviewer for journals and NIHR i4i programme.
Editorial	Guest editor, British Journal of Psychiatry special issue on DMTs in AD (2023)

## Key Collaborations

University of Manchester	Prof Stuart Allan (Neuroscience, MaVRICS), Prof Adam Greenstein (CV Sciences), Prof Laura Parkes (Neuroimaging, AllinOne), Dr Sasha Philbert (CV Sciences, Na-MRI), Dr Karen Hampson (Vision Science, retinal biomarkers), Dr Jenna Littlejohn (Hearing BRC, ABHAD)
--------------------------	---

## Professional Memberships

- Royal College of Psychiatrists (2010–)
- British Geriatric Society (2017–)
- International Psychogeriatric Association (2019–)
- International Parkinson's and Movement Disorders Society (2018–)

## References

Available upon request